Nanding, Norseda P.

HRN: 26-85-39  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/10/2025
CO-AMOXICLAV 625MG (TAB)
04/10/2025
04/16/2025
PO
500mg
BID
Nsvd 3rd Degree
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Prophylaxis    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: